India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Artificial intelligence is speeding ahead, but real estate is discovering a hard truth: AI can’t work well on messy, inconsistent, and siloed data. Unlike finance or e‑commerce, the industry has never agreed on shared definitions or standardized frameworks, making it difficult for AI tools to interpret information at scale. Now, leaders across real estate are realizing that the real breakthrough won’t come from smarter algorithms—it will come from finally unifying the industry’s fragmented data so AI can deliver its full value.
Manhattan’s iconic Waldorf Astoria is hitting the market again—and its billion‑dollar price tag may reveal whether commercial real estate is finally recovering. After years of inflation, shutdowns, and stalled investment, new forecasts from major firms show growing optimism, making this sale a critical test for the 2026 market.
Homeowners across Florida are facing sharp increases in their escrow payments as insurance premiums continue to rise. With insurers leaving the state, rates climbing, and replacement policies costing far more, many residents are experiencing sudden spikes in their monthly mortgage bills. These escalating insurance-driven escrow costs are reshaping affordability, influencing buyer qualifications, and redefining financial stability for Floridians and the broader real estate market.
The modern MLS marketplace is one of real estate’s greatest success stories: transparent, efficient, and designed to help buyers and sellers win. But its very effectiveness has sparked a new risk — professionals looking to “stand out” by limiting exposure and restricting information. Research shows that full MLS visibility can boost a seller’s price by $50,000 to $75,000, yet off‑market tactics threaten to chip away at the system that delivers those gains. The MLS doesn’t need replacing; it needs thoughtful upgrades and well‑trained professionals who know how to protect and leverage its power.
Florida homeowners are being hit with a new kind of sticker shock as rising insurance premiums push escrow payments sharply higher, adding hundreds of dollars to monthly mortgage bills. The surge is reshaping budgets, impacting buyer qualification, and redefining affordability across the state. With insurers pulling back and premiums climbing faster than wages, both current owners and hopeful buyers must now navigate a market where insurance risk—not just home price—plays a major role in the true cost of living in the Sunshine State.
Florida’s mobile and manufactured homes are surging in popularity, but insuring them requires specialized HO-7 coverage designed for structures built off-site and more vulnerable to wind and weather. With rising premiums, unique risks, and new 2026 market shifts, homeowners and industry professionals need to understand what these policies cover, what they don’t, which insurers are leading the pack, and how to save without sacrificing protection.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
